Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $175.73, for a total transaction of $966,515.00. Following the completion of the sale, the vice president now owns 24,482 shares of the company’s stock, valued at approximately $4,302,221.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
NYSE:EW opened at $178.02 on Friday. Edwards Lifesciences Corp has a 1 year low of $123.00 and a 1 year high of $178.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92. The company has a market capitalization of $36.45 billion, a PE ratio of 37.88, a PEG ratio of 2.26 and a beta of 0.90.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The company had revenue of $977.70 million during the quarter, compared to analysts’ expectations of $973.72 million. During the same quarter in the previous year, the company posted $0.94 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Corp will post 5.21 EPS for the current year.
Large investors have recently bought and sold shares of the company. Executive Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $25,000. Sontag Advisory LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Lindbrook Capital LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Institutional investors own 83.29% of the company’s stock.
A number of brokerages have commented on EW. UBS Group raised their price target on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Tuesday. Citigroup raised their price target on shares of Edwards Lifesciences from $119.00 to $130.00 and gave the stock a “sell” rating in a research note on Monday, February 25th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target on shares of Edwards Lifesciences in a research note on Sunday, February 3rd. Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Monday, February 4th. Finally, Morgan Stanley raised their price target on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the stock an “overweight” rating in a research note on Friday, December 7th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $171.10.
ILLEGAL ACTIVITY WARNING: “Donald E. Bobo, Jr. Sells 5,500 Shares of Edwards Lifesciences Corp (EW) Stock” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2019/03/15/donald-e-bobo-jr-sells-5500-shares-of-edwards-lifesciences-corp-ew-stock.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.